Best Free GLP-1 Tracker App in 2026: How to Pick One That Fits

The best free GLP-1 tracker app is the one that fits your medication and the routine you will actually keep, not the one that shouts "free" the loudest. Almost every popular GLP-1 app, including GlucoPal and Shotsy, is freemium: free to download, with an optional paid tier. So the honest question is not "which app is free," it is "which free tier covers what I need."

This guide explains what "free" really means in this category, sets evaluation criteria based on fit instead of price, and compares the real options (Shotsy, MeAgain, GlucoPal, MyNetDiary, and Glapp) on what each does best. Ratings here come from a live App Store data pull on June 29, 2026, so review the current listing before you download.

What does "free" really mean for a GLP-1 tracker app?

"Free" in this category almost always means freemium: the app is free to download and covers core tracking, while advanced features sit behind a paid tier. Shotsy, MeAgain, GlucoPal, and most others follow this pattern. Knowing where each app draws its free-versus-paid line matters far more than which app calls itself "free."

Most "free" GLP-1 apps are freemium, and that is fine if you know the line

Most GLP-1 tracker apps marketed as "free" are freemium. You can download and start logging without paying, but features like advanced analytics, projected medication-level charts, or unlimited history may require a subscription. This is a normal model, not a trick, as long as you know where the line sits.

The confusion comes from marketing. Some app sites describe themselves as "completely free" while still selling a yearly premium tier. That phrasing is what sends people searching "is Shotsy free" after they hit a locked feature. The useful framing is simple: nearly all of these apps are free to start, and most have an optional paid upgrade. Your job is to check whether the free tier covers the things you personally need, like your specific medication, injection-site tracking, or nutrition logging.

Free to download vs free forever: where the paywall usually sits

Free to download does not mean free forever. The paywall in GLP-1 apps usually sits around the same handful of features: estimated medication-level charts, deeper analytics, data export, and sometimes longer history. Core dose logging, reminders, and weight tracking are typically in the free tier.

For example, Shotsy is free to download and keeps core tracking free, while its premium tier (roughly $39.99 to $49.99 per year, per its App Store listing) unlocks medication-level estimation charts. GlucoPal is also free to download and use, with an optional GlucoPal Pro upgrade ($9.99/mo or $29.99/yr) that unlocks its estimated medication-level forecast chart. The pattern repeats across the category: the most "advanced" projection and analytics features are usually the paid ones, and the everyday logging you do most often is usually free.

Why "which app is cheapest" is the wrong first question

Price should not be your first filter, because the cheapest app is useless if it does not support your medication or the routine you will keep. The better first question is fit: does this app track your exact GLP-1, handle injection-site rotation, and stay easy enough that you open it every dose day?

Research backs this up. In a 2026 JMIR analysis of 126,553 tirzepatide users, people who engaged with digital tracking lost 22.9% of body weight at 12 months, compared with 17.5% for non-engaged users. Engagement, not price, tracked with results. So the smarter sequence is fit first, friction second, and price last. A free app you abandon in two weeks is more expensive, in the only way that matters, than a fitting app you keep.

Which free GLP-1 tracker app is the best fit for me?

The best fit depends on your medication, your phone, and how much depth you want. Shotsy fits people who want deep medication-level charts or Android. GlucoPal fits iPhone users who want the widest medication coverage plus nutrition and side-effect tracking in one app. MeAgain suits gamified, all-in-one tracking; MyNetDiary suits nutrition-first users; Glapp suits minimalists.

Quick-pick comparison table (iTunes-verified ratings, June 29, 2026)

Best free GLP-1 tracker apps (2026): The top-rated GLP-1 trackers with free tiers are Shotsy (4.84 stars, ~25,900 ratings), MeAgain (4.80 stars, ~21,300 ratings), GlucoPal (4.8 stars, ~4,000 global ratings, 80,000+ users), MyNetDiary GLP-1 Companion (4.76 stars, ~1,215 ratings), and Glapp (4.74 stars, ~632 ratings). All are free to download; each draws its paid line in a different place.

Ratings reflect a live App Store data pull on June 29, 2026 and move weekly. GlucoPal's ~4,000 figure is global App Store ratings (about 2,065 in the US). None of these apps is medical advice.

GlucoPal: widest medication coverage in one weight-loss tracker

GlucoPal is the best fit for iPhone users who want the widest US weight-loss medication coverage in a single tracker. It is free to download and use with no account required, so most people can start logging in under a minute. An optional GlucoPal Pro upgrade ($9.99/mo or $29.99/yr) unlocks the estimated medication-level forecast chart.

What sets it apart is how much of the GLP-1 weight-loss journey it covers in one place. On medications, GlucoPal handles the full US weight-loss range, including Zepbound, Wegovy (injection and pill), Mounjaro, Ozempic, and compounded semaglutide or tirzepatide, so you are not stuck if you switch forms or formulations. Around that it layers an injection-site body map, a symptom journal tied to the dose timeline, weight trends with weekly averages, progress photos, and full nutrition tracking (protein, calorie, and water goals, a meal database, AI meal scanning, and automatic calorie goals that adjust to your activity), all syncing through Apple Health. For most people that means one tracker instead of a medication logger plus a separate calorie counter. It is rated 4.8 stars and trusted by 80,000+ people. The main limit: GlucoPal is iPhone-only today, so Android users should look elsewhere for now.

Shotsy: deep charts, Android, and a popular community

Shotsy is the best fit if you want deep medication-level charts, Android availability, or the largest user community in the category. It is free to download with core tracking free, and its premium tier (roughly $39.99 to $49.99 per year, per its App Store listing) unlocks estimated medication-level charts and advanced analytics.

With about 25,900 ratings at 4.84 stars, Shotsy has the most reviews of any app here, which is a genuine signal of staying power and active development. It supports a broad list of GLP-1 medications, offers strong scheduling tools, and runs on both iOS and Android, an edge GlucoPal does not match yet. If your main goal is analytical depth or you are on Android, Shotsy is a strong pick. Our GlucoPal vs Shotsy comparison walks through where each one fits.

MeAgain, MyNetDiary, and Glapp: where each fits

MeAgain, MyNetDiary, and Glapp each fit a narrower user. MeAgain suits people who want gamified, all-in-one tracking; MyNetDiary suits nutrition-first users; Glapp suits minimalists who want a simple shot log.

MeAgain (4.80 stars, ~21,300 ratings) pairs food logging, progress visuals, and engagement mechanics, which some users find genuinely motivating. Note that MeAgain's most full-featured tracking requires a subscription, so its free experience is more limited than Shotsy's or GlucoPal's. MyNetDiary GLP-1 Companion (4.76 stars, ~1,215 ratings) is fundamentally a strong calorie counter with a GLP-1 add-on, so it shines on nutrition but lacks an injection-site body map. Glapp (4.74 stars, ~632 ratings) is clean and lightweight, a good fit if you want a simple log and not much else, though its medication coverage is lighter.

What features actually matter in a free GLP-1 tracker?

The features that matter most are medication coverage, injection-site rotation, built-in nutrition tracking, and low-friction access like Apple Health sync and no forced account. Price tier matters last. These are the things that decide whether an app fits your routine and whether you will keep using it.

Medication coverage: orals, compounded, and brand injections

Medication coverage is where many "free" GLP-1 apps quietly fall short. US readers may be on a brand injection, a compounded formulation, or an oral GLP-1, and not every app supports all three. If your app cannot log your exact medication and form, the rest of its features barely matter.

This is a real US-specific gap. Some people use compounded semaglutide or tirzepatide, and others use oral options like the Wegovy pill or Rybelsus. Most established apps, Shotsy included, handle the common brand injections, so the question that actually separates them is whether an app also covers compounded formulations and daily orals. GlucoPal covers the full US weight-loss range in one tracker, including Zepbound, Wegovy (injection and pill), Mounjaro, Ozempic, and compounded semaglutide or tirzepatide, so you are not stuck if you switch forms or formulations. If you are on a daily pill rather than a weekly shot, check that the app is actually built for daily dosing and not just weekly injections. Compounded availability has narrowed since the 2025 shortage resolution, so confirm your supply with your pharmacy, and make sure your tracker can record whatever form you end up on.

Injection-site rotation and a body map

An injection-site body map matters because rotating sites is part of the official instructions, not an optional nicety. Shotsy also tracks your injection sites and suggests the next one, and GlucoPal shows where you last injected on a visual body map so you can rotate at a glance. Either approach beats guessing, which matters because non-rotation is the leading driver of skin changes. Some other apps, including MyNetDiary and Glapp, do not offer site tracking at all.

The clinical reason is lipohypertrophy, thickened lumps of tissue that can form when you inject the same spot repeatedly. A review of 26 studies covering 12,493 self-injecting patients found roughly 38% prevalence, with failure to rotate sites the strongest risk factor. FDA labeling for medications like Zepbound instructs patients to rotate injection sites within the abdomen, thigh, or upper arm. A body map turns "where did I inject last week?" into a glance instead of a guess. If you want the detail, see our guide to injection-site rotation and why it matters.

Nutrition, protein, and AI meal scanning without a second app

Built-in nutrition tracking matters because GLP-1 medications lower appetite, and many people struggle to hit protein targets. An app that logs protein, calories, and water alongside your dose saves you from running a separate calorie counter. AI meal scanning lowers the friction further by estimating macros from a photo.

This is where a dedicated calorie counter and a dedicated GLP-1 tracker pull in different directions. MyNetDiary leans nutrition-first, while apps like Shotsy and GlucoPal fold nutrition into a medication-centered timeline. GlucoPal adds protein, calorie, and water goals plus AI meal scanning, so you can log a meal in seconds instead of searching a database. If you want the reasoning behind targets, our guide to protein goals on GLP-1 covers how much to aim for and why it helps preserve muscle during weight loss.

Apple Health sync, reminders, and no-account access

Low-friction access decides whether you keep using an app. Apple Health sync, dose reminders, and no forced account all remove steps between you and your first log. The fewer barriers at the start, the more likely the habit sticks, which is what actually drives results.

GlucoPal syncs steps, activity, weight, water, and meals through Apple Health automatically, sends dose reminders so you do not miss an injection or pill, and requires no account to start, so most people can begin logging in under a minute. Shotsy integrates with Apple Health too, so the clearest difference here is the no-account start, which lowers the barrier to actually beginning. (On storage, GlucoPal uses iCloud for backups much like Shotsy, so the real advantage here is the no-account start, not the storage model.) GlucoPal also states it does not sell your information and that you control your health data.

Does it matter which tracker you use, or just that you use one?

Both matter, but consistency matters most. Research links engaging with tracking to better weight-loss outcomes, and the biggest risk is quitting the app, not picking a slightly "wrong" one. So pick an app that fits your medication and feels easy enough to keep using, then actually keep using it.

What the research says about tracking and weight loss

People who engage with digital tracking tend to lose more weight. In a 2026 JMIR analysis of 126,553 tirzepatide users, engaged users lost 22.9% of body weight at 12 months versus 17.5% for non-engaged users, and were 2.88 times more likely to reach at least 20% weight loss. This is an association, not proof that an app causes weight loss, but it is a strong reason to track.

The takeaway is practical. The benefit comes from staying engaged over months, not from any single app's feature list. That points back to fit and friction: choose the tracker you will still be opening at month six, because that is the behavior tied to the outcome. Talk to your clinician about your own targets, since individual results vary widely.

The real risk is quitting the app, not picking the "wrong" one

The biggest risk is abandoning tracking altogether, not choosing a slightly imperfect app. Real-world data shows only about 32.3% of patients remain persistent on GLP-1 therapy at one year. If staying on the medication is hard, staying engaged with a tracker is part of what helps you notice progress and problems early.

That reframes the whole decision. Do not agonize over which app has one extra chart. Pick the one that supports your medication, makes daily logging fast, and does not require a frustrating setup, then commit to it. A low-friction app you keep open beats a feature-packed app you delete. If side effects are your main worry, an app with a side-effect journal tied to your dose timeline can help you spot patterns worth raising with your prescriber.

Is Shotsy free, and is it worth paying for?

Shotsy is free to download and use for core GLP-1 tracking, and freemium beyond that: a premium tier (about $39.99 to $49.99 per year, per its App Store listing) unlocks medication-level estimation charts and advanced analytics. You only pay if you want those projection features, so whether the subscription is worth it depends on how much you value them, and on how Shotsy's free tier compares with the alternatives.

Is the Shotsy subscription worth it, or is another app a better fit?

The Shotsy subscription is worth it if estimated medication-level charts and advanced analytics are central to how you track, or if you are on Android or value the largest community. Before paying, though, the fairer move is to compare free tiers on fit rather than on price alone.

That is where GlucoPal is worth a look, not as a cheaper clone but as a different fit. It is purpose-built for GLP-1 weight loss with the widest US medication coverage in one app, plus an injection-site body map, full nutrition tracking with AI meal scanning, Apple Health sync, and no account required to start. GlucoPal is also freemium: free to download and use, with a Pro upgrade ($9.99/mo or $29.99/yr, comparable to Shotsy's annual tier) that unlocks its own estimated forecast chart. For iPhone users who want broad medication coverage and a fast, no-account start, GlucoPal is the stronger fit; for Android users or chart-first power users, Shotsy holds the edge. Our full Shotsy comparison breaks down the details.

FAQ

Is there a free GLP-1 tracker app?

Yes, several GLP-1 tracker apps are free to download and use, including Shotsy, GlucoPal, MeAgain, MyNetDiary, and Glapp. Most are freemium, meaning core tracking is free while advanced features (like medication-level charts) sit behind an optional subscription. Check each app's free tier against the features you actually need, especially support for your specific medication.

What is the best app to track GLP-1?

The best GLP-1 tracker is the one that fits your medication and routine. For iPhone users wanting the widest US weight-loss medication coverage in one app, GlucoPal is a strong choice (4.8 stars, 80,000+ users). For deep medication-level charts or Android, Shotsy leads. For nutrition-first tracking, MyNetDiary fits. Pick the app you will keep using, since engagement is what tracks with results.

What is the difference between GlucoPal and Shotsy?

GlucoPal is iPhone-only and purpose-built for GLP-1 weight loss, with the widest US medication coverage, an injection-site body map, AI meal scanning, Apple Health sync, and no account required to start (Pro $9.99/mo or $29.99/yr adds a forecast chart). Shotsy runs on iOS and Android, has the larger community (~25,900 ratings), and leans into estimated medication-level charts in its premium tier (about $39.99 to $49.99 per year). Both are free to download.

Sources

1. 01.JMIR (2026) - Digital engagement and tirzepatide weight loss outcomes (n=126,553) - engaged users lost 22.9% vs 17.5% of body weight at 12 months and were 2.88x more likely to reach at least 20% weight loss.
2. 02.PMC11293763 - Real-world GLP-1 persistence - only about 32.3% of patients remain persistent on GLP-1 therapy at one year.
3. 03.PMC5934253 - Lipohypertrophy prevalence - review of 26 studies (12,493 participants) finding ~38% prevalence among self-injecting patients.
4. 04.PMC11924065 - Injection-site rotation and lipohypertrophy risk - non-rotation of injection sites as a leading risk factor.
5. 05.DailyMed - Zepbound Prescribing Information - FDA labeling instructing patients to rotate injection sites.
6. 06.Lilly - Zepbound Instructions for Use - manufacturer instructions for rotating within the abdomen, thigh, or upper arm.
7. 07.App Store - Shotsy GLP-1 Tracker - rating count (~25,900 at 4.84), freemium premium pricing (~$39.99-$49.99/yr), and supported features, verified June 29, 2026.
8. 08.App Store - Zepbound Tracker by GlucoPal - GlucoPal availability, rating (4.8), feature list, and supported medications, verified June 29, 2026.